ENOB - Enochian BioSciences discovers two sets of altered animal data in two of its studies

• After an internal review of its scientific data, Enochian BioSciences ( NASDAQ: ENOB ) has discovered that a former scientific advisor had altered and falsified two sets of animal data before the company's scientists could review it.
• "One data set was for an inhaled COVID-19 treatment study while the other was for a (hepatitis B virus) therapy study," the biotech company said in a statement on Friday.
• As a result of its discovery, the company said it would initiate legal action against the former scientific advisor, Serhat Gumrukçu.
• ENOB said that its investigation verified certain data from the COVID-19 and (hepatitis B virus) pipelines.
• "The company is evaluating its internal control regarding the review and verification of external scientific data and will modify as appropriate," ENOB said.
• ENOB stock -4.7% to $1.84 in aftermarket trading.

For further details see: